DIA
Drug Information Association Logo

Orphan Drugs in the USA, European Union, and Japan

| Online

« Back to Listing

Overview 

This course, a Thomson Reuters Cortellis Regulatory Online Learning module, examines the orphan drug development programs established in the United States, EU, and Japan to encourage the research and development of orphan products. For the three regions, the course outlines the legislative and regulatory basis of the orphan pharmaceutical development programs; describes administrative, scientific, and financial incentives available to orphan drug sponsors; and explores the supervisory bodies and authorities involved in the pharmaceutical designation processes.

Featured Topics 

  • Legislative and regulatory basis of the orphan pharmaceutical development programs
  • Administrative, scientific, and financial incentives available to orphan drug sponsors
  • Supervisory bodies and authorities involved in the pharmaceutical designation processes

Learning Objectives 

Participants who complete this course should be able to:

  • Identify legislative and regulatory basis of the orphan drug development programmes in the United States, European Union, and Japan
  • Discuss the role of the supervisory bodies and authorities involved
  • Examine the incentives available to orphan drug sponsors
  • Describe the different orphan drug designation processes
  • Compare the orphan drug programmes in the three regions

The course takes an average of 1.5 hours to complete.

Contact Information 

Linda Belmont, DIA
Phone +1.215.293.5818
Linda.Belmont@diahome.org

Technical Requirements 

Click here for minimum system requirements.

Registration Fees 

Other Fees

Individual
$495.00
Register Online

Unless otherwise disclosed, the statements made by speakers represent their own opinions and not necessarily those of the organization they represent, or that of the Drug Information Association. Speakers, agenda and CE information are subject to change without notice. Recording of any DIA educational material in any type of media is prohibited without prior written consent from DIA.

« Back to Listing Back To Top